SCIENMAG: Medicine & Health

AUGUST 8, 2023

Some HIV-1 carriers who have received an early antiretroviral treatment during several years are able to control the virus for a long term after treatment interruption. For the first time, teams of scientists from the Institut Pasteur, Inserm and the Paris Public Hospital […]

Virus 89

Virus Hospitals Treatment 89

Broad Institute

APRIL 25, 2024

Sabeti and her lab had also responded quickly to Ebola in 2014, working with hospitals and government officials in Sierra Leone to sequence viral genomes from patients and make the data available to local communities. Ozonoff is also an associate professor of pediatrics at Harvard Medical School and a scientist at Boston Children’s Hospital.

Virus 132

Virus Hospitals Disease Government 132

Broad Institute

JUNE 25, 2024

Results of the study — which represents a collaboration across Brigham and Women’s Hospital, the Broad Institute of MIT and Harvard, and Harvard T.H. Co-first authors on the paper are Zhendong Mei of and Women’s Hospital and Broad, and Fenglei Wang of Harvard Chan School and Broad.

Virus 135

Virus Hospitals Disease Nurses 135

Broad Institute

JUNE 18, 2024

Simple test for flu could improve diagnosis and surveillance By Allessandra DiCorato June 18, 2024 Breadcrumb Home Simple test for flu could improve diagnosis and surveillance A low-cost CRISPR-based paper strip test distinguishes between influenza types and can be reprogrammed to recognize different viruses including the H5N1 bird flu virus.

Virus 144

Virus RNA Laboratories Medical Schools 144

Drugs.com

JULY 17, 2023

MONDAY, July 17, 2023 (HealthDay Now) -- Parents now have a new long-acting drug to protect their children against respiratory syncytial virus (RSV), a common germ that hospitalizes as many as 3% of children under the age of 1 in the United States.

FDA Approval 100

FDA Approval Virus FDA Hospitals 100

SCIENMAG: Medicine & Health

JANUARY 16, 2024

In early 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a highly contagious and pathogenic virus, made its alarming debut and quickly spread worldwide, causing the novel coronavirus (COVID-19) pandemic that threatened human health and public safety.

Virus 93

Virus Hospitals 93

SCIENMAG: Medicine & Health

JULY 13, 2023

As a result of the COVID-19 pandemic, respiratory syncytial virus (RSV) surges in young children occurred outside the usual November to March season, when immune-based prophylactic is available to protect children at high risk for severe illness.

Hospitals 70

Hospitals Virus 70

The Pharma Data

DECEMBER 9, 2020

9, 2020 — In a sign that the COVID-19 pandemic is entering its most dire stage yet, new federal data show that more than a third of Americans now live in areas where hospitals are critically short of intensive care beds. WEDNESDAY, Dec. When you don’t have that capacity, that means people will die.”

Hospitals 52

Hospitals Doctors Virus Government 52

The Pharma Data

APRIL 7, 2022

announced today that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV). NYSE: PFE) and ReViral Ltd.

Virus 52

Virus Vaccine Clinical Development Hospitals 52

Broad Institute

JANUARY 30, 2024

He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.

Hospitals 137

Hospitals Virus Medical Schools Science 137

The Pharma Data

APRIL 8, 2022

Using a Human Lung Chip that replicates the structures and functions of the lung air sac, or “alveolus,” the research team discovered that applying mechanical forces that mimic breathing motions suppresses influenza virus replication by activating protective innate immune responses. . During his Ph.D.

Virus 52

Virus Immune Response Disease Clinical Trials 52

The Pharma Data

JANUARY 29, 2021

SARS-CoV-2 Seroconversion Tied to Out-of-Hospital Sudden Deaths. from Lenox Hill Hospital in New York City, and colleagues examined the association between OHSD and SARS-CoV-2 epidemiologic burden during the first wave of the COVID-19 pandemic across neighborhoods of NYC. Professional. FRIDAY, Jan. FRIDAY, Jan. Coleman, R.N.,

Hospitals 52

Hospitals Virus Research 52

The Pharma Data

DECEMBER 1, 2020

1, 2020 — Yet another grim record for COVID-19 hospitalizations was set on Monday, as more than 96,000 patients battled severe cases of the virus in hospital wards across America. But the number of hospitalizations have risen by more than 12 percent over the past week, the newspaper noted. TUESDAY, Dec.

Hospitals 52

Hospitals Vaccine Virus Government 52

Codon

AUGUST 26, 2024

When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus. Unsubscribe any time.

RNA 97

RNA Virus DNA Vaccine 97

Broad Institute

FEBRUARY 8, 2024

By Allessandra DiCorato February 8, 2024 Credit: NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland Scanning electron image of the Lassa virus budding off a cell. Other scientists had discovered that this gene was critical for the Lassa virus to enter cells.

Research 81

Research Virus Hospitals Disease 81

Codon

AUGUST 27, 2024

Consider Alice, a 49-year-old woman (and hypothetical patient) who walked into a hospital in Puerto Rico with joint pain, a headache, nausea, and a low fever. While Alice was lucky that her infections were identified at the hospital, it would have been even better had they been identified before she arrived.

DNA 97

DNA Laboratories Hospitals Virus 97

The Pharma Data

MARCH 23, 2022

“When the COVID-19 pandemic started, our multidisciplinary research teams switched our investigations of other viruses and bacteria to focus on a potential treatment for what was then a challenging new virus for us,” says Children’s Center microbiologist Lori Jones-Brando, Ph.D., alone each year.

Virus 52

Virus Immune Response Research Treatment 52

SCIENMAG: Medicine & Health

JULY 19, 2023

An article […]

Production 69

Production Hospitals Virus Research 69

The Pharma Data

NOVEMBER 16, 2020

16, 2020 (American Heart Association News) — The rate of resuscitation for cardiac arrests outside of a hospital setting decreased during the first weeks of the COVID-19 pandemic, new research shows. The researchers looked at 52,183 out-of-hospital cardiac arrest cases in the U.S. MONDAY, Nov. “That was unexpected.

Hospitals 52

Hospitals Science Virus Research 52

The Pharma Data

APRIL 27, 2023

RSV causes over 270,000 hospitalisations and approximately 20,000 in-hospital deaths in adults aged 60 years and older each year in Europe. This is the first time an RSV vaccine candidate for adults has gained a positive opinion, one of the final steps in the marketing authorisation procedure prior to approval by the European Commission.

Virus 40

Virus Vaccine Trials Clinical Trials 40

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

DECEMBER 3, 2020

Another record-breaking day of COVID-19 hospitalizations and deaths underscored Redfield’s grim warning. The number of people hospitalized for COVID-19 on Wednesday passed 100,000, nearly double the highest point seen last spring. With hospitals filling up in multiple states, the days ahead do appear bleak.

Hospitals 52

Hospitals Vaccine Long-Term Care Facilities Nurses 52

The Pharma Data

MAY 16, 2022

million symptomatic cases of the virus, as well as 690,000 hospitalizations and more than 110,000 deaths. The profound health and economic impact of the Pfizer-BioNTech vaccine during its first year of rollout in the US is described in detail in a new study in the peer-reviewed Journal of Medical Economics.

Vaccine 52

Vaccine Hospitals Virus Disease 52

The Pharma Data

MARCH 3, 2022

If approved by the FDA, this maternal immunization has the potential to be the first vaccine candidate to help protect infants in their vulnerable first months of life from disease caused by this highly-contagious virus. Burden of RSV RSV is a contagious virus and a common cause of respiratory illness. Pfizer Inc.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

JUNE 2, 2022

Orencia was one of two immune modulators that improved survival for people hospitalized with COVID-19. Treatment with Orencia versus placebo displayed a strong but not statistically significant improvement in the primary endpoint of time to recovery as measured by day of hospital discharge.

Hospitals 52

Hospitals Treatment Clinical Trials Science 52

The Pharma Data

OCTOBER 30, 2020

(NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. About the REGN-COV2 Trial in Hospitalized Patients. Cohort 1A: patients not requiring oxygen.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 128

Therapies Virus DNA Clinical Trials 128

The Pharma Data

JUNE 7, 2023

RSV is a common, contagious respiratory virus that leads to over 270,000 hospitalisations and approximately 20,000 in-hospital deaths each year in adults aged 60 years and over in Europe. The authorisation is based on GSK’s landmark positive pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial data.

Virus 40

Virus Vaccine Disease Trials 40

The Pharma Data

JANUARY 13, 2021

patients hospitalized with COVID-19. Patient Population: 45 hospitalized patients with COVID-19. Primary Endpoint: Proportion of patients recovered from COVID-19 and no longer hospitalized at Day 29. LONDON and RALEIGH, N.C., David Zaccardelli, Pharm. For more information, please visit www.veronapharma.com.

Hospitals 52

Hospitals Clinical Trials Therapies Treatment 52

Broad Institute

JULY 11, 2024

Targeted drug treatment leads tumor cells to imitate viral infection By Ari Navetta July 11, 2024 Breadcrumb Home Targeted drug treatment leads tumor cells to imitate viral infection Exploiting "viral mimicry," mIDH1 inhibitors trick tumors into thinking they are infected with a virus. paper cited Wu M, Kondo H, et al.

Treatment 72

Treatment Immune Response Drugs Virus 72

The Pharma Data

JANUARY 26, 2021

“The death toll from COVID-19 continues to rise around the world and hospitalizations, particularly in the U.S., These data further support our belief that bamlanivimab and etesevimab together have the potential to be an important treatment that significantly reduces hospitalizations and death in high-risk COVID-19 patients.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

Codon

FEBRUARY 27, 2024

Patient YY’s neighbors quickly started to become infected, passing on the virus in turn. While the consensus that emerged among experts was that the virus spread primarily via airborne transmission , it also made use of another route: fomite transmission. Puzzled, epidemiologists sought to understand the source of the outbreak.

Virus 69

Virus Hospitals Production Regulations 69

The Pharma Data

NOVEMBER 5, 2020

Regeneron announced today an update from the independent data monitoring committee (DMC) for the United Kingdom-based RECOVERY trial evaluating REGN-COV2 in hospitalized patients with COVID-19.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

PLOS: DNA Science

JULY 27, 2023

The owners of the felines all reported feeding their pets raw meat, and samples of the meat revealed not only flu virus genetic material, but also infectious virus. The fear is that a variant of the deadly virus might emerge that infects people, and, worst-case-scenario, passes from person to person. emerged in late 2021.

Disease 95

Disease DNA Virus RNA 95

The Pharma Data

FEBRUARY 1, 2021

HOUSTON, TX, February 01, 2021 /24-7PressRelease/ — It has been just over a year since the COVID-19 virus arrived in the United States, already claiming the lives of over 400,000 Americans. Medical professionals are desperately seeking effective treatments as hospitals are continuously overwhelmed with COVID-19 patients.

Treatment 52

Treatment Virus Hospitals Pharmaceutical Companies 52